In vivo CRISPR/Cas9 targeting of fusion oncogenes for selective elimination of cancer cells

In vivo CRISPR/Cas9 targeting of fusion oncogenes for selective elimination of cancer cells

Fusion oncogenes (FO) are common in cancers, but specific targeting of these chimeric genes are challenging. Here the authors report a CRISPR/Cas9 strategy that targets two intronic regions to disrupt the FOs in cancer cells and show that this approach reduces tumour growth and prolongs survival in...

Descripción completa

Guardado en:
Detalles Bibliográficos
Autores principales: M. Martinez-Lage, R. Torres-Ruiz, P. Puig-Serra, P. Moreno-Gaona, M. C. Martin, F. J. Moya, O. Quintana-Bustamante, S. Garcia-Silva, A. M. Carcaboso, P. Petazzi, C. Bueno, J. Mora, H. Peinado, J. C. Segovia, P. Menendez, S. Rodriguez-Perales
Formato: article
Lenguaje:EN
Publicado: Nature Portfolio 2020
Materias:
Science
Q
Acceso en línea:https://doaj.org/article/734f530d0a9c4f49995b0d8094e4f389
Etiquetas: Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!

Internet

https://doaj.org/article/734f530d0a9c4f49995b0d8094e4f389

Ejemplares similares